Kryptomed Formulations Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 10-12-2024
- Paid Up Capital ₹ 0.10 M
as on 10-12-2024
- Company Age 8 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 44.25%
(FY 2022)
- Profit 79.28%
(FY 2022)
- Ebitda 214.00%
(FY 2022)
- Net Worth 70.66%
(FY 2022)
- Total Assets 28.48%
(FY 2022)
About Kryptomed Formulations
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Kirti Mehta, Anshul Madan, and Vipin Kumar serve as directors at the Company.
- CIN/LLPIN
U24230CH2016PTC041139
- Company No.
041139
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Jul 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Kryptomed Formulations Private Limited offer?
Kryptomed Formulations Private Limited offers a wide range of products and services, including Pharma & Bioanalytical Services, Pharmaceutical Third Party Manufacturing, Body Lotions, Moisturizing Lotion, Common Disease Medicines, Hair Growth Medicine, Antibacterial Drugs, Clindamycin & Nicotinamide Gel, Pharma Franchise, PCD Pharma Franchise.
Who are the key members and board of directors at Kryptomed Formulations?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kirti Mehta  | Director | 20-Jul-2016 | Current |
| Anshul Madan | Director | 20-Jul-2016 | Current |
| Vipin Kumar | Director | 20-Jul-2016 | Current |
Financial Performance of Kryptomed Formulations.
Kryptomed Formulations Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 44.25% increase. The company also saw a substantial improvement in profitability, with a 79.28% increase in profit. The company's net worth Soared by an impressive increase of 70.66%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kryptomed Formulations?
In 2022, Kryptomed Formulations had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Kryptomed Formulations?
Unlock and access historical data on people associated with Kryptomed Formulations, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kryptomed Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kryptomed Formulations's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
